Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The sarcoma treatment and burden of illness in North America and Europe (SABINE) study

Peter Reichardt, Michael Leahy, Xavier Garcia Del Muro, Stefano Ferrari, Javier Martin, Hans Gelderblom, Jingshu Wang, Arun Krishna, Jennifer Eriksson, Arthur Staddon, Jean Yves Blay

Research output: Contribution to journalArticle

Abstract

The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.

Original languageEnglish
Article number740279
JournalSarcoma
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Cost of Illness
North America
Sarcoma
Quality of Life
Bone and Bones
Therapeutics
Health
Weights and Measures
Drug Therapy
Pain
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Quality of life and utility in patients with metastatic soft tissue and bone sarcoma : The sarcoma treatment and burden of illness in North America and Europe (SABINE) study. / Reichardt, Peter; Leahy, Michael; Garcia Del Muro, Xavier; Ferrari, Stefano; Martin, Javier; Gelderblom, Hans; Wang, Jingshu; Krishna, Arun; Eriksson, Jennifer; Staddon, Arthur; Blay, Jean Yves.

In: Sarcoma, Vol. 2012, 740279, 2012.

Research output: Contribution to journalArticle

Reichardt, P, Leahy, M, Garcia Del Muro, X, Ferrari, S, Martin, J, Gelderblom, H, Wang, J, Krishna, A, Eriksson, J, Staddon, A & Blay, JY 2012, 'Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The sarcoma treatment and burden of illness in North America and Europe (SABINE) study', Sarcoma, vol. 2012, 740279. https://doi.org/10.1155/2012/740279
Reichardt, Peter ; Leahy, Michael ; Garcia Del Muro, Xavier ; Ferrari, Stefano ; Martin, Javier ; Gelderblom, Hans ; Wang, Jingshu ; Krishna, Arun ; Eriksson, Jennifer ; Staddon, Arthur ; Blay, Jean Yves. / Quality of life and utility in patients with metastatic soft tissue and bone sarcoma : The sarcoma treatment and burden of illness in North America and Europe (SABINE) study. In: Sarcoma. 2012 ; Vol. 2012.
@article{b5c6fe77f753453c8cc851b75754ff18,
title = "Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The sarcoma treatment and burden of illness in North America and Europe (SABINE) study",
abstract = "The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.",
author = "Peter Reichardt and Michael Leahy and {Garcia Del Muro}, Xavier and Stefano Ferrari and Javier Martin and Hans Gelderblom and Jingshu Wang and Arun Krishna and Jennifer Eriksson and Arthur Staddon and Blay, {Jean Yves}",
year = "2012",
doi = "10.1155/2012/740279",
language = "English",
volume = "2012",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Quality of life and utility in patients with metastatic soft tissue and bone sarcoma

T2 - The sarcoma treatment and burden of illness in North America and Europe (SABINE) study

AU - Reichardt, Peter

AU - Leahy, Michael

AU - Garcia Del Muro, Xavier

AU - Ferrari, Stefano

AU - Martin, Javier

AU - Gelderblom, Hans

AU - Wang, Jingshu

AU - Krishna, Arun

AU - Eriksson, Jennifer

AU - Staddon, Arthur

AU - Blay, Jean Yves

PY - 2012

Y1 - 2012

N2 - The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.

AB - The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84859729299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859729299&partnerID=8YFLogxK

U2 - 10.1155/2012/740279

DO - 10.1155/2012/740279

M3 - Article

C2 - 22550425

AN - SCOPUS:84859729299

VL - 2012

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 740279

ER -